A clinical study in oncology has shown that cannabis oil provides a significant reduction in nerve damage during the initial part of the treatment. The study was carried out at the Department of Clinical Oncology at Zealand's University Hospital in Roskilde, where the VibroSense Meter® II was used to investigate how the vibration sensibility is affected throughout the treatment.
The current study is part of a research-collaboration between VibroSense Dynamics and Zealand's University Hospital in Roskilde, with the aim of improving treatment of cancer with chemotherapy. The results from the double-blind study showed a significant reduction in acute nerve damage for the patients who received cannabis oil.
In an ongoing follow-up study, it will be investigated whether the positive effect for treatment with cannabis oil is persistent after 6 and 12 months after the end of treatment.
"The result is very promising and if the positive effect is permanent, this could lead to a completely new and additional treatment method. In the study, the VibroSense Meter® II was used and the researchers are very satisfied with the instrument, which they believe is easy to use and it also provides strong support in the diagnosis of chemotherapy-induced nerve damage. I see this as an important step towards our goal that the VibroSense Meter® II will be used as a standard tool in the treatment of cancer with chemotherapy", says Hans Wallin CEO of VibroSense Dynamics AB.
About Nerve damage during chemotherapy
Nerve damage caused by chemotherapy is a very common complication that can cause lifelong disabilities.The dosage of chemotherapy is routinely adjusted according to body surface area, which is a simple but unfortunately very rough tool for determining the right doses.
Many reports show that the therapeutic effects and severe nerve damage at a given dose can vary significantly between patients with the same body functions, the same diagnosis, histology and disease stage.
According to the latest edition of the World Cancer Report 2020, roughly 19 million new cancer diagnoses are made per year, of which approximately 2.26 million (11.7%) are breast cancer, 2.20 million (11.4%) lung cancer and 1.9 million (10%) colorectal cancer. In the United States alone, the care of cancer patients costs roughly USD 208 billion per year.
Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se
“The new Gold Standard for reliable
detection of nerve damage”
About VibroSense Dynamics AB ( publ )
VibroSense Dynamics AB ( publ ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.
Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.